Independent association of atherogenic dyslipidaemia with all-cause mortality in individuals with type 2 diabetes and modifying effect of gender: A prospective cohort study

Emanuela Orsi  
Ospedale Maggiore di Milano Policlinico: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Giuseppe Penno  
University of Pisa: Universita degli Studi di Pisa

Anna Solini  
University of Pisa: Universita degli Studi di Pisa

Enzo Bonora  
University of Verona: Universita degli Studi di Verona

Cecilia Fondelli  
Siena University Hospital: Azienda Ospedaliera Universitaria Senese

Roberto Trevisan  
Azienda Ospedaliera Papa Giovanni XXIII: Aziende Socio Sanitarie Territoriale Papa Giovanni XXIII

Monica Vedovato  
Università degli Studi di Padova: Universita degli Studi di Padova

Franco Cavalot  
Università degli Studi di Torino: Universita degli Studi di Torino

Susanna Morano  
Sapienza University of Rome: Universita degli Studi di Roma La Sapienza

Marco Giorgio Baroni  
University of Aquila: Universita degli Studi dell'Aquila

Antonio Nicolucci  
CORESEARCH

Giuseppe Pugliese  
Università degli Studi di Roma La Sapienza Facolta di Medicina e Psicologia  
https://orcid.org/0000-0003-1574-0397

Original investigation
Abstract

Background

Increased LDL cholesterol is a major risk factor for morbidity and mortality from cardiovascular disease, though this association is attenuated by the widespread use of statins. Moreover, despite attainment of LDL cholesterol goals, a residual cardiovascular risk remains, partly attributed to atherogenic dyslipidaemia, the relationship of which with all-cause death has not been sufficiently explored. This analysis evaluated the independent association of atherogenic dyslipidaemia with total mortality in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events Italian Multicentre Study.

Methods

This observational, prospective study enrolled 15,773 patients in 19 Diabetes Clinics throughout Italy in the years 2006–2008. Triglycerides and total and HDL cholesterol were measured by colorimetric enzymatic methods, whereas LDL cholesterol was estimated using the Friedewald formula. Vital status was retrieved on 31 October 2015 for 15,656 patients (99.3%). Participants were stratified by quartiles of triglycerides, HDL cholesterol, and triglyceride:HDL cholesterol ratio (TG:HDL).

Results

A total of 3,602 deaths occurred over a follow-up 7.42 ± 2.05 years (31.0 × 1,000 person-years). In the unadjusted analyses, the highest TG:HDL (but not triglyceride) and the lowest HDL cholesterol quartile were associated with increased death rate and mortality risk. When sequentially adjusting for confounders, including total or LDL cholesterol and lipid-lowering treatment, mortality risk was significantly higher in the highest triglyceride (hazard ratio 1.167 [95% confidence interval 1.055–1.291], \( p = 0.003 \)) and TG:HDL (1.192 [1.082–1.314], \( p < 0.0001 \)) and the lowest HDL cholesterol (1.232 [1.117–1.360], \( p < 0.0001 \)) quartile, though the association of triglycerides and HDL cholesterol disappeared after further adjustment for each other. Interaction with gender was significant only for HDL cholesterol (\( p = 0.0009 \)). The relationship with death was stronger for triglycerides in males and HDL cholesterol in females, with the latter remaining even after adjustment for triglycerides (1.366 [1.176–1.587], \( p < 0.0001 \), for the lowest vs the highest quartile).

Conclusions

In patients with type 2 diabetes, higher triglycerides and TG:HDL and lower HDL cholesterol were independently associated with increased all-cause mortality, with a modifying effect of gender for triglycerides and HDL cholesterol. These data suggest that atherogenic dyslipidaemia, especially TG:HDL, may serve as predictor of death in these individuals.

Trial registration
ClinicalTrials.gov, NCT00715481, 15 July, 2008.

Background

Diabetes is associated with excess mortality mainly, but not exclusively from cardiovascular disease (CVD) [1]. Increased LDL cholesterol is a major risk factor for atherosclerotic CVD, as consistently shown by observational and Mendelian randomization studies in people with and without diabetes [2]. In addition, intervention trials with statins and other cholesterol reducing agents have provided evidence that lowering LDL cholesterol is highly effective in both primary and secondary prevention of CVD [3], with no difference between patients with and without diabetes [4]. However, despite attainment of LDL cholesterol goals, a residual CVD risk remains, part of which has been attributed to increased levels of other apolipoprotein (Apo) B-containing lipoproteins, including smaller triglycerides-rich lipoproteins (TRLs) and their remnant particles, and the associated inverse changes in HDL cholesterol [5]. This lipid pattern, which is called atherogenic dyslipidaemia, is a common feature in conditions characterized by insulin resistance, such as type 2 diabetes and the other abnormalities clustering in the metabolic syndrome [5].

Concentrations of both triglycerides and HDL cholesterol were shown to be associated with CVD risk, though only HDL cholesterol was an independent predictor of CVD events [6]. The association of triglyceride levels with coronary heart disease was in fact attenuated by adjustment for HDL cholesterol and abrogated by adjustment for non-HDL cholesterol, suggesting that causality is related to cholesterol content in remnant particles rather than to triglyceride levels [7]. Conversely, Mendelian randomization studies have suggested causality for triglycerides [7], but not for HDL cholesterol [6], though most genetic variants associated with either triglycerides or HDL cholesterol are also associated with other lipids [8]. Consistently, intervention trials have shown that fibrates and omega-3 fatty acids, which predominantly reduce triglyceride levels, were effective beyond statin treatment in reducing CVD risk in patients with atherogenic dyslipidaemia [9–13], including those with diabetes [10, 13] or hyperinsulinemia [13]. In contrast, no additional benefits were observed upon treatment with niacin [14] or cholesteryl ester transfer protein inhibitors [15], which primarily target reduced HDL cholesterol.

The existing literature on the relationship of lipid levels with all-cause death is not as abundant as that regarding CVD mortality, especially in type 2 diabetes. Previous studies have found increased total mortality at both ends of the lipid spectrum in the general population, with differences depending on the characteristic of the study sample, i.e., general versus disease-specific population, younger versus older individuals, and Caucasian versus other ethnicities, and reflecting differences in causes of death and circulating lipid concentrations. Among Caucasians, individuals with higher total and LDL cholesterol levels had greater mortality risk [16, 17], though a few studies found U-shaped or inverse relationships [18, 19], whereas, in East Asian populations [20, 21] and Pima Indians [22], the highest risk for all-cause mortality was reported in people with low total cholesterol. Moreover, the U-shaped or negative relationships of lipids (positive for HDL cholesterol) with all-cause mortality have been associated with older age [16, 23] and smoking [18] and attributed to a significant contribution of deaths from cancer,
infections, and alcohol-related disorders (including liver disease and accidents) [16–18, 20]. However, low lipid levels appear to be a consequence of these conditions rather than playing a causal role in the associated increase in mortality [24].

In people with type 2 diabetes, intervention trials with statins have shown that reduction of LDL cholesterol levels was associated with decreased mortality from CVD, but not from any cause [25]. In a previous report from the Renal Insufficiency And Cardiovascular Events (RIACE) cohort, we showed that total and LDL cholesterol were inversely associated with all-cause mortality, a finding attributed to an indication effect. In fact, prevalence of statin treatment at baseline was less than 50%, suggesting that it was restricted to high-risk patients, who therefore showed higher mortality rate associated with lower cholesterol levels than those at lower risk [26]. This interpretation is consistent with previous data indicating that the association between cholesterol and CVD in contemporary studies may be attenuated by the preferential use of statins by high-risk individuals [27].

The present analysis aimed at assessing the independent association of atherogenic dyslipidaemia with death from any cause in the large RIACE cohort of individuals with type 2 diabetes.

Methods

Design

The RIACE Italian Multicentre Study is an observational, prospective, cohort study on the impact of estimated glomerular filtration rate (eGFR) on morbidity and mortality in individuals with type 2 diabetes [26, 28].

Patients

The study population included 15,773 Caucasian patients (after excluding 160 individuals with missing or implausible values), consecutively attending 19 hospital-based, tertiary referral Diabetes Clinics of the National Health Service throughout Italy in the years 2006–2008. Exclusion criteria were dialysis or renal transplantation.

All-cause mortality

The vital status of study participants on 31 October 2015 was verified by interrogating the Italian Health Card database (http://sistemats1.sanita.finanze.it/wps/portal/), which provides updated and reliable information on all current Italian residents [29].

Baseline measurements

Baseline data were collected using a standardized protocol across participating centres [26, 28].

Participants underwent a structured interview in order to collect the following information: age at the time of the interview, smoking status, known diabetes duration, co-morbidities, and current glucose-, lipid-, and
blood pressure (BP)-lowering treatments.

Body mass index (BMI) was calculated from weight and height, whereas waist circumference was estimated from log-transformed BMI values; BP was measured with a sphygmomanometer with the patients seated with the arm at the heart level.

Haemoglobin A\textsubscript{1c} (HbA\textsubscript{1c}) was measured by HPLC using DCCT-aligned methods; triglycerides and total and HDL cholesterol were determined in fasting blood samples by colorimetric enzymatic methods. The triglyceride:HDL cholesterol ratio (TG:HDL) was then calculated by dividing triglyceride for HDL cholesterol levels (both in mg/dl) and LDL cholesterol concentration was estimated using the Friedewald formula.

The presence of diabetic kidney disease (DKD) was assessed by measuring albuminuria and serum creatinine, as previously detailed [28, 30]. Albumin excretion rate was obtained from 24-hour urine collections or calculated from albumin-to-creatinine ratio in early-morning, first-voided urine samples, using a conversion formula developed in patients with type 1 diabetes and preliminarily validated in a subgroup of RIACE participants. Albuminuria was measured in fresh urine samples by immunonephelometry or immunoturbidimetry, in the absence of interfering clinical conditions. One-to-three measurements for each patient were obtained; in cases of multiple measurements, the geometric mean of 2–3 values was used for analysis. In individuals with multiple measurements, the concordance rate between the first value and the geometric mean was > 90% for all albuminuria categories [30]. Serum (and urine) creatinine was measured by the modified Jaffe method, traceable to IDMS, and eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [26]. Patients were then classified into Kidney Disease: Improving Global Outcomes categories of albuminuria (A1 to A3) and eGFR (G1 to G5) and assigned to one of the following DKD phenotypes: no DKD (i.e., A1G1-A1G2), albuminuria alone (albuminuric DKD with preserved eGFR, i.e., A2G1-A2G2-A3G1-A3G2), reduced eGFR alone (non-albuminuric DKD, i.e., A1G3-A1G4-A1G5), or both albuminuria and reduced eGFR (albuminuric DKD with reduced eGFR, i.e., A2G3-A2G4-A2G5-A3G3-A3G4-A3G5), as previously reported [26].

In each centre, the presence of diabetic retinopathy (DR) was assessed by an expert ophthalmologist by dilated fundoscopy [31]. Patients with mild or moderate non-proliferative DR were classified as having non-advanced DR, whereas those with severe non-proliferative DR, proliferative DR, or maculopathy were grouped into the advanced, sight threatening DR category. DR grade was assigned based on the worse eye.

Previous major acute CVD events, including myocardial infarction; stroke; foot ulcer/gangrene/amputation; and coronary, carotid, and lower limb revascularization, were adjudicated based on hospital discharge records by an ad hoc committee in each centre [32].

**Statistical analysis**

For the purpose of the current analysis, the whole RIACE cohort and men and women separately were divided into quartiles of triglycerides, HDL cholesterol, and TG:HDL.
Data are expressed as mean ± SD or median (interquartile range) for continuous variables, and number of cases and percentage for categorical variables. Comparisons among quartiles were performed by one-way ANOVA or Kruskal–Wallis test, according to the parametric or non-parametric distribution of continuous variables, followed by Bonferroni correction or Mann-Whitney test, respectively, for post-hoc comparisons, and by Pearson's \( \chi^2 \) test for categorical variables.

Crude mortality rates were described as events per 1,000 patient-years, with 95% exact Poisson confidence intervals (CIs) and adjusted for age and gender by a Poisson regression model. Kaplan-Meier survival probabilities for all-cause mortality were estimated according to the above categorizations and differences were analysed using the log-rank statistic. The hazard ratios (HRs) and their 95% CIs were estimated by Cox proportional hazards regression, using the lowest triglyceride, the highest HDL cholesterol or the lowest triglyceride TG:HDL quartile as reference. These analyses were adjusted for age and gender (model 1), plus CVD risk factors, i.e., smoking, diabetes duration, \( \text{HbA}_1c \), BMI, total cholesterol (or LDL cholesterol), and systolic and diastolic BP, and treatments, i.e., anti-hyperglycaemic, lipid-lowering, and anti-hypertensive therapy (model 2), plus presence of complications, i.e., DKD phenotypes, DR grade and any CVD, and/or severe comorbidity(ies), i.e., chronic obstructive pulmonary disease, chronic liver disease and/or cancer (model 3), and, for triglycerides and HDL cholesterol quartiles only, plus HDL cholesterol and triglyceride levels, respectively, as continuous variables (model 4). Appropriate tests were applied for assessing the interaction between gender and quartiles of triglycerides, HDL cholesterol, and TG:HDL and the analyses were then replicated separately for men and women. Finally, all the above analyses were rerun after substituting LDL cholesterol for total cholesterol and the association between HDL cholesterol and mortality was evaluated also among individuals falling in the lowest quartile of LDL cholesterol.

All \( p \) values were two-sided, and a \( p < 0.05 \) was considered statistically significant. Statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).

Results

Valid information on vital status was retrieved for 15,656 participants (99.3% of the cohort). At the time of the census, 3,602 (23.0%) individuals had died; death rate was 31.0 per 1,000 person-years (95% CI 30.0–32.0) over a follow-up of 7.4 ± 2.1 years [26].

**Association of triglycerides, HDL cholesterol and TG:HDL with all-cause mortality in the whole cohort**

The clinical features of study participants stratified by quartiles of triglycerides, HDL cholesterol, and TG:HDL are shown in Tables S1-3. Patients falling in the fourth (highest) quartile of triglycerides or TG:HDL or in the first (lowest) quartile of HDL cholesterol were younger, less frequently smokers, and had shorter diabetes duration, but worse CVD risk profile and higher prevalence of complications than those
falling in the first (lowest) quartile of triglycerides and TG:HDL or in the fourth (highest) quartile of HDL cholesterol.

Crude mortality rates were similar among quartiles of triglycerides; however, when adjusted for age and gender, mortality rates became significantly higher in quartiles III and IV versus quartile I (Table 1). Kaplan-Meier estimates (Fig. 1A) and unadjusted HRs (not shown) did not differ among quartiles of triglycerides. When sequentially adjusting for confounders (models 1–3), mortality risk became significantly higher in quartiles III and IV versus quartile I (Fig. 1B-D), but differences disappeared after further adjustment for HDL cholesterol (HR, 1.039 [95% CI, 0.940–1.149], \( p = 0.450 \) for quartile III, and 1.066 [0.952–1.194], \( p = 0.269 \) for quartile IV).

Crude and age- and gender-adjusted mortality rates were higher for quartile I of HDL cholesterol (and only the adjusted rates for quartile II) versus quartile IV (Table 1). Kaplan-Meier estimates (Fig. 2A) and unadjusted (not shown) and adjusted (models 1–3, Fig. 2B-D) HRs were also higher for quartile I versus quartile IV, except after further adjustment for triglycerides (0.968 [0.786–1.191], \( p = 0.756 \)).

Crude and age- and gender-adjusted mortality rates were higher for quartile IV (and only the adjusted rates for quartile III) versus quartile I of TG:HDL (Table 1). Kaplan-Meier estimates (Fig. 3A) and unadjusted (not shown) and adjusted (Fig. 3B-D) HRs were also higher for quartile IV and III (only in the adjusted analyses) versus quartile I.
Table 1
Mortality rates in study participants with valid information on vital status on October 31 2015, stratified by quartiles of triglycerides, HDL cholesterol, and TG:HDL.

|       | N   | Events | Percent events | Events per 1,000 patient-years (95% CI), unadjusted | p       | Events per 1,000 patient-years (95% CI), age- & gender-adjusted | p       |
|-------|-----|--------|-----------------|----------------------------------------------------|---------|-----------------------------------------------------------------|---------|
|       |     |        |                 |                                                   |         |                                                                  |         |
|       |     |        |                 |                                                   | 0.666   | < 0.0001                                                        |         |
| Triglycerides |    |        |                 |                                                   |         |                                                                  |         |
| I     | 3,992 | 897   | 22.5            | 30.25 (28.33–32.29)                                | Ref.    | 11.02 (9.60–12.64)                                              | Ref.    |
| II    | 3,839 | 886   | 23.1            | 31.09 (29.11–33.20)                                | 0.563   | 11.82 (10.35–13.50)                                             | 0.138   |
| III   | 3,933 | 929   | 23.6            | 32.03 (30.03–34.15)                                | 0.222   | 12.76 (11.20–14.54)                                             | 0.002   |
| IV    | 3,892 | 890   | 22.9            | 30.76 (28.80–32.85)                                | 0.722   | 14.10 (12.39–16.05)                                             | < 0.0001|
| HDL cholesterol |    |        |                 |                                                   | < 0.0001| < 0.0001                                                        |         |
| I     | 4,025 | 1,061 | 26.4            | 36.53 (34.39–38.79)                                | < 0.0001| 18.16 (15.81–20.86)                                             | < 0.0001|
| II    | 3,982 | 881   | 22.1            | 29.68 (27.78–31.70)                                | 0.566   | 13.68 (11.94–15.68)                                             | 0.008   |
| III   | 3,769 | 818   | 21.7            | 29.01 (27.09–31.07)                                | 0.921   | 12.55 (10.98–14.36)                                             | 0.392   |
| IV    | 3,880 | 842   | 21.7            | 28.87 (26.98–30.88)                                | Ref.    | 12.03 (10.60–13.66)                                             | Ref.    |
| TG:HDL |       |        |                 |                                                    | 0.056   | < 0.0001                                                        |         |
| I     | 3,914 | 863   | 22.1            | 29.48 (27.58–31.51)                                | Ref.    | 11.02 (9.65–12.59)                                              | Ref.    |
| II    | 3,916 | 869   | 22.2            | 29.79 (27.87–31.83)                                | 0.829   | 11.83 (10.36–13.50)                                             | 0.143   |
| III   | 3,915 | 927   | 23.7            | 32.12 (30.12–34.25)                                | 0.070   | 13.18 (11.56–15.03)                                             | < 0.0001|
| IV    | 3,911 | 943   | 24.1            | 32.76 (30.73–34.91)                                | 0.025   | 15.51 (13.60–17.70)                                             | < 0.0001|

TG:HDL = triglyceride:HDL cholesterol ratio; CI = confidence interval.
Results did not change when LDL cholesterol was substituted for total cholesterol (not shown). Moreover, the negative association of HDL cholesterol with all-cause mortality was detected also in the lowest quartile of LDL cholesterol (≤ 2.21 mmol/L) cholesterol (not shown).

**Association of triglycerides, HDL cholesterol and TG:HDL with all-cause mortality by gender**

Interaction with gender was significant for HDL cholesterol ($p = 0.009$), but not for triglyceride and TG:HDL quartiles. The clinical features of male and female participants stratified by quartiles of triglycerides, HDL cholesterol, and TG:HDL did not differ appreciably compared with those of the whole cohort (not shown).

No differences among quartiles of triglycerides were observed in crude mortality rates in both males and females, whereas age-adjusted death rates were increased only in male participants (Table 2).

Likewise, no differences among quartiles of triglycerides were detected in Kaplan-Meier estimates (Additional file 3: Figures S1A and S2A) and in unadjusted HRs (not shown) in both males and females. Among male participants, Cox proportional hazards regression analysis showed an increased mortality risk for quartiles III and IV vs quartile I after sequential adjustment for confounders (Additional file 3: Figure S1B-D), including HDL cholesterol levels in case of quartile IV (1.161 [1.019–1.324], $p = 0.025$). Conversely, an increased risk of death was observed among female participants only for quartile IV vs quartile I when adjusted for age, gender and CVD risk factors (Additional file 3: Figure S2B-C), but not when complications/comorbidities (Additional file 3: Figure S2D) and HDL cholesterol levels (0.942 [0.785–1.130], $p = 0.522$) were included in the model.

Crude mortality rates according to quartiles of HDL cholesterol were not different in males, but were significantly higher for quartile I vs quartile IV in females, whereas higher age-adjusted death rates were observed for quartile I vs quartile IV in both males and females (Table 2). Kaplan-Meier estimates (Additional file 3: Figures S3A and S4A) and the unadjusted HRs (not shown) did not differ in males, but were significantly higher for quartile I vs quartile IV in females (1.514 [1.315–1.742], $p < 0.0001$). Likewise, no difference in the adjusted HRs were detected in male participants, except for a higher risk for quartile I vs quartile IV after including complications/comorbidities in the model (Additional file 3: Figure S3B-D), but not after further adjustment for triglycerides (1.059 [0.922–1.215], $p = 0.419$). In contrast, in female participants, Cox proportional hazards regression analysis showed a significantly higher risk of death for quartile I vs quartile IV after sequential adjustment for confounders (Additional file 3: Figures S4B-D), including triglyceride levels (1.366 [1.176–1.587], $p < 0.0001$).

Crude mortality rates by quartiles of TG:HDL were not different, whereas age-adjusted death rates were significantly higher for quartiles III and IV vs quartile I in both males and females (Table 2). No differences among quartiles of TG:HDL were observed in Kaplan-Meier estimates (Additional file 3: Figures S5A and S6A) and in unadjusted HRs (not shown) in males, whereas in females unadjusted risk of death was higher for quartile IV vs quartile I (1.234 [1.065–1.430], $p = 0.005$). Cox proportional hazards
regression analysis showed a significantly higher risk of death for quartile III and IV vs quartile I in male participants after sequential adjustment for confounders (Additional file 3: Figure S5B-D) and in female participants after adjustment for age, gender and CVD risk factors, but not for complications/comorbidities (Additional file 3: Figure S6B-D).
Table 2
Mortality rates in male and female study participants with valid information on vital status on October 31 2015, stratified by quartiles of triglycerides, HDL cholesterol, and TG:HDL.

|                  | N     | Events | Percent events | Events per 1,000 patient-years (95% CI), unadjusted | p       | Events per 1,000 patient-years (95% CI), age- & gender-adjusted | p       |
|------------------|-------|--------|----------------|----------------------------------------------------|---------|---------------------------------------------------------------|---------|
| **Triglycerides**|       |        |                |                                                    |         |                                                               |         |
| **Males**        |       |        |                |                                                    |         |                                                               |         |
| I                | 2,219 | 539    | 24.3           | 33.09 (30.41-36.00)                                 | 0.507   | 22.71 (20.70-24.91)                                           | < 0.0001|
| II               | 2,224 | 538    | 24.2           | 32.75 (30.09-35.64)                                 | 0.865   | 23.36 (21.31-25.61)                                           | 0.640   |
| III              | 2,212 | 569    | 25.7           | 35.34 (32.56-38.37)                                 | 0.273   | 26.25 (24.01-28.69)                                           | 0.016   |
| IV               | 2,247 | 541    | 24.1           | 32.57 (29.94-35.44)                                 | 0.796   | 30.15 (27.63-32.90)                                           | < 0.0001|
| **Females**      |       |        |                |                                                    |         |                                                               |         |
| I                | 1,651 | 330    | 20.0           | 26.46 (23.75-29.47)                                 | 0.471   | 18.72 (16.65-21.05)                                           | 0.154   |
| II               | 1,710 | 374    | 21.9           | 29.36 (26.53-32.49)                                 | 0.167   | 20.68 (18.49-23.12)                                           | 0.188   |
| III              | 1,701 | 347    | 20.4           | 27.11 (24.40-30.11)                                 | 0.753   | 20.27 (18.11-22.70)                                           | 0.300   |
| IV               | 1,692 | 364    | 21.5           | 28.75 (25.94-31.86)                                 | 0.274   | 22.25 (19.93-24.84)                                           | 0.023   |
| **HDL cholesterol**|      |        |                |                                                    | 0.023   |                                                               | < 0.0001|
| **Males**        |       |        |                |                                                    |         |                                                               |         |
| I                | 2,038 | 542    | 26.6           | 36.98 (33.99-40.22)                                 | 0.210   | 32.14 (29.42-35.11)                                           | < 0.0001|
| II               | 2,200 | 509    | 23.1           | 31.21 (28.61-34.04)                                 | 0.120   | 25.08 (22.88-27.49)                                           | 0.304   |
| III              | 2,377 | 559    | 23.5           | 31.70 (29.17-34.44)                                 | 0.184   | 22.76 (20.79-24.91)                                           | 0.564   |
| IV               | 2,287 | 577    | 25.2           | 34.30 (31.61-37.21)                                 | Ref.    | 23.55 (21.53-25.76)                                           | Ref.    |

TG:HDL = triglyceride:HDL cholesterol ratio; CI = confidence interval.
|   | N  | Events | Percent events | Events per 1,000 patient-years (95% CI), unadjusted | p           | Events per 1,000 patient-years (95% CI), age- & gender-adjusted | p           |
|---|----|--------|----------------|---------------------------------------------------|-------------|----------------------------------------------------------------|-------------|
| Females |     |        |                |                                                   |             |                                                                  |             |
| I | 1,654 | 443    | 26.8           | 37.29 (33.98–40.93)                               | < 0.0001    | 28.93 (26.12–32.05)                                               | < 0.0001    |
| II | 1,709 | 322    | 18.8           | 24.79 (22.22–27.65)                               | 0.985       | 18.77 (16.70–21.09)                                               | 0.136       |
| III | 1,576 | 305    | 19.4           | 25.62 (22.90–28.67)                               | 0.685       | 18.83 (16.72–21.22)                                               | 0.131       |
| IV | 1,815 | 345    | 19.0           | 24.82 (22.33–27.58)                               | Ref.        | 16.71 (14.88–18.76)                                               | Ref.        |
| TG:HDL |     |        |                |                                                   |             |                                                                  |             |
| Males |     |        |                |                                                   | 0.656       |                                                                  | < 0.0001    |
| I | 2,223 | 535    | 24.1           | 32.63 (29.97–35.51)                               | Ref.        | 21.62 (19.69–23.74)                                               | Ref.        |
| II | 2,228 | 537    | 24.1           | 32.64 (30.00–35.53)                               | 0.992       | 23.38 (21.33–25.62)                                               | 0.202       |
| III | 2,226 | 565    | 25.4           | 34.87 (32.11–37.87)                               | 0.270       | 26.80 (24.53–29.29)                                               | < 0.0001    |
| IV | 2,225 | 550    | 24.7           | 33.58 (30.89–36.51)                               | 0.633       | 30.80 (28.23–33.59)                                               | < 0.0001    |
| Females |     |        |                |                                                   | 0.051       |                                                                  | < 0.0001    |
| I | 1,686 | 325    | 19.3           | 25.31 (22.70–28.22)                               | Ref.        | 17.33 (15.39–19.52)                                               | Ref.        |
| II | 1,689 | 347    | 20.5           | 27.33 (24.60–30.36)                               | 0.321       | 19.66 (17.54–22.03)                                               | 0.103       |
| III | 1,690 | 354    | 21.0           | 27.98 (25.22–31.06)                               | 0.191       | 20.69 (18.49–23.16)                                               | 0.022       |
| IV | 1,689 | 389    | 23.0           | 31.15 (28.21–34.41)                               | 0.006       | 24.41 (21.93–27.17)                                               | < 0.0001    |

TG:HDL = triglyceride:HDL cholesterol ratio; CI = confidence interval.

**Discussion**
This analysis of patients with type 2 diabetes from the RIACE cohort showed a positive association of triglycerides and TG:HDL and a negative association of HDL cholesterol with all-cause mortality in a gender-specific manner. The relationship between triglycerides and death was in fact stronger in males, though interaction with gender was not significant, at variance with that of HDL cholesterol, which was a powerful predictor of mortality especially in females.

The independent association of atherogenic dyslipidaemia with all-cause death is consistent with previous results in patients with type 2 diabetes showing a positive relationship with total mortality for triglycerides [33] and TG:HDL [34] and a negative relationship with CVD morbidity and mortality for HDL cholesterol [35, 36]. In contrast, among Pima Indians with diabetes, a negative relationship was observed between TG:HDL and all-cause mortality, together with no significant association for triglycerides and U-shaped relationships for total, LDL, and non-HDL cholesterol [22]. However, lower, not higher, concentrations of triglycerides, TG:HDL, and total, LDL, and non-HDL cholesterol were associated with higher total mortality also in individuals without diabetes, suggesting that findings in this population reflect the predominance of causes of death other than CVD [22]. Moreover, HDL cholesterol levels were not related to CVD events or all-cause mortality in high-risk patients with type 2 diabetes from the Second Manifestations of ARTERial disease cohort [37]. In this study, a positive association was found in individuals with LDL cholesterol < 2.0 mmol/L and a negative association was observed in those with LDL cholesterol 2.0-2.5 mmol/L (for CVD events only) [37]. However, in the RIACE participants with low LDL cholesterol levels, we confirmed the negative association between HDL cholesterol and all-cause death detected in the whole cohort.

Altogether, the current and previous findings from the RIACE cohort provide further insights into the understanding of the association of lipid levels with all-cause death by supporting the concept that atherogenic dyslipidaemia characterizing patients with type 2 diabetes plays a major role in the excess mortality of these individuals by conferring an independent risk of death, predominantly by CVD. Moreover, our results indicate that triglyceride and HDL cholesterol levels (and TG:HDL) might perform better than total and LDL cholesterol as predictors of all-cause death in these individuals and that achieving triglyceride and HDL cholesterol goals is particularly important in individuals with type 2 diabetes, despite the fact that current guidelines primarily recommend attaining the LDL cholesterol target with statins and other cholesterol reducing agents [8].

It remains unclear whether the increased mortality risk associated with atherogenic dyslipidaemia is attributable to the altered circulating levels of triglycerides and/or HDL cholesterol per se or to the related changes in TRLs (and remnant cholesterol) and HDL function, respectively, which however may not be accurately reflected in the lipid profile and might be better predicted by ApoB and ApoA-I, respectively [38]. In addition, the increased all-cause (and CVD) mortality associated with atherogenic dyslipidaemia may be related to the elevated levels of small dense LDLs. These particles are in fact known to be atherogenic because of increased penetration and retention in the vascular wall, due to their reduced size and increased affinity for proteoglycans [39], and decreased affinity for the LDL receptor, due to their enhanced susceptibility to oxidation [40].
A unique observation of our study is the modifying effect of gender. Previous gender-specific differences in the association between lipids and mortality were reported only for total cholesterol [16, 23], though not consistently [19, 21]. Our observation has important clinical implications for patients with type 2 diabetes. In fact, risk stratification of these individuals should take into consideration the different impact of triglycerides and HDL cholesterol on mortality in males and females, though it is advisable to achieve the recommended goals for both these lipid fractions regardless of gender. In this view, the TG:HDL may be a better predictor than either one for all-cause death and should be preferentially used for estimating mortality risk in people with type 2 diabetes.

Strength of our study include the large sample size, the assessment of a wide range of clinical parameters, and the completeness of baseline and follow-up data. However, there are several limitations. First, the lack of information on the causes of death and on possible confounders such as alcohol consumption, though we considered the presence of comorbidities which may be associated with low lipid levels and high mortality. Second, lack of measurements of lipid profile and lack of information on lipid-lowering treatments over time. In particular, at baseline, there was a relatively low prevalence of statin treatment (42.5%) and a very low prevalence of treatment with other lipid-lowering agents (omega-3 4.9%, fibrates 2.5%, ezetimibe 1.0%, and resins 0.1%) as well as a negligible percentage of dual (4.4%) or triple (0.2%) therapy. These prevalence rates have likely changed significantly during the follow-up period, thus resulting in changes in lipid levels. Fourth, the study findings may not be applicable to the general ambulatory diabetes population, as only part of the individuals with type 2 diabetes attend Diabetes Clinics in Italy. Finally, the observational design makes causal interpretation impossible.

**Conclusion**

In patients with type 2 diabetes, atherogenic dyslipidaemia was independently associated with all-cause death, at variance with total or LDL cholesterol. There was a stronger impact on mortality of triglycerides in males and HDL cholesterol in females, suggesting that TG:HDL may be the best lipid marker for predicting death from any cause in these individuals.

**Abbreviations**

CVD = cardiovascular disease; Apo = apolipoprotein; TRLs = triglycerides-rich lipoproteins; RIACE = Renal Insufficiency And Cardiovascular Events; eGFR = estimated glomerular filtration rate; BP = blood pressure; BMI = body mass index; HbA$_1c$ = haemoglobin A$_1c$; TG:HDL = triglyceride:HDL cholesterol ratio; DKD = diabetic kidney disease; DR = diabetic retinopathy; CI = confidence interval; HR = hazard ratio.

**Declarations**

**Ethics approval and consent to participate:** The study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the ethics committee of the coordinating centre.
(Sant’Andrea Hospital, Rome, Italy) on 25 September 2006 (number 43/2006) and subsequently by the ethics committee of each participating centre. Participants provided an informed consent.

Consent for publication: Not applicable.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: EO: consulting fees from Eli Lilly and Novo Nordisk; GPe: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sigma-Tau, and Takeda, and travel grants from AstraZeneca, Novo Nordisk, and Takeda; AS: consulting fees from AstraZeneca, Boehringer Ingelheim, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and MundiPharma; EB: consulting fees from Abbot, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Bruno Farmaceutici, Eli Lilly, Janssen, Johnson&Johnson, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Roche, Sanofi-Aventis, Servier, and Takeda, and research grants from AstraZeneca, Genzyme, Menarini Diagnostics, Novo Nordisk, Roche, and Takeda; CF: lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk and travel grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Sanofi-Aventis, and Takeda; RT: consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-Aventis, and lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; MV: lecture fees from Lifescan and Novo Nordisk; FC: lecture fees from AstraZeneca, Sanofi-Aventis, and Takeda; SM: lecture fees from AstraZeneca, Sanofi-Aventis, and Takeda; MB: lecture fees from Abbot, Astra-Zeneca, Mundi Pharma, Novo Nordisk, Sanofi-Aventis; grant support from Sanofi-Aventis; AN: consulting fees from AstraZeneca, Pikdare, and Roche, lecture fees from AstraZeneca, Boehringer Ingelheim, Medtronic, and Novo Nordisk, and research grants from Aboca, AstraZeneca, Eli Lilly, Novo Nordisk, Sanofi-Aventis, and Theras; GPu: consulting fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, MundiPharma, Novartis, Novo Nordisk, Sigma-Tau, Takeda, and travel grants from AstraZeneca, Laboratori Guidotti, Sanofi-Aventis, and Takeda.

Funding: This research was supported by the Research Foundation of the Italian Diabetes Society (Diabete Ricerca) and the Diabetes, Endocrinology and Metabolism (DEM) Foundation, and by unconditional grants from Eli-Lilly, Sigma-Tau, Takeda, Chiesi Farmaceutici, and Boehringer-Ingelheim. The funding sources had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors’ contributions: EO, GPe, AS, AN, and GPu conceived and designed the study. All authors contributed to data acquisition, analysis, or interpretation. EO and GPu drafted the article and had full access to all the data and took responsibility for the integrity of data and accuracy of the data analysis in this study. GPe, AS, EB, CF, RT, MV, FC, SM, MB, and AN revised the manuscript critically for essential intellectual content. All authors approved the submitted version of the manuscript and agreed to be
personally accountable for the individual’s own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**Acknowledgments:** The Authors thank the RIACE Investigators for participating in this study (see the complete list in the Additional file 1: The RIACE Study Group).

**References**

1. Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med.* 2011;364:829–841.

2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2017;38:2459–2472.

3. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. 2016;316:1289–1297.

4. Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. 2008;371:117–125.

5. Ferrari R, Aguiar C, Alegria E, Bonadonna RC, Cosentino F, Elisaf M, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. *Eur Heart J Suppl.* 2016;18(Suppl C):C2–C12.

6. Rader DJ, Hovingh GK. HDL and cardiovascular disease. 2014;384:618–625.

7. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. 2014;384:626–635.

8. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J.* 2020;41:111–188.

9. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med.* 1999;341:410–418.

10. Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care.* 2009;32:493–498.

11. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 2010;362:1563–1574.
12. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *N Engl J Med.* 2019;380:11–22.

13. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). *Arch Intern Med.* 2002;162:2597–2604.

14. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med.* 2011;365:2255–2267.

15. Armitage J, Holmes MV, Preiss D. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2019;73:477–487.

16. Cai J, Pajak A, Li Y, Shestov D, Davis CE, Rywik S, et al. Total cholesterol and mortality in China, Poland, Russia, and the US. *Ann Epidemiol.* 2004;14:399–

17. Cowan LD, O’Connell DL, Criqui MH, Barrett-Connor E, Bush TL, Wallace RB. Cancer mortality and lipid and lipoprotein levels. Lipid research clinics program mortality follow-up study. *Am J Epidemiol.* 1990;131:468–482.

18. D’Agostino RB, Belanger AJ, Kannel WB, Higgins M. Role of smoking in the U-shaped relation of cholesterol to mortality in men. The Framingham study. *Am J Epidemiol.* 1995;141:822–827.

19. Harris T, Feldman JJ, Kleinman JC, Ettinger Jr WH, Makuc DM, Schatzkin AG. The low cholesterol-mortality association in a national cohort. *J Clin Epidemiol.* 1992;45:595–601.

20. Song YM, Sung J, Kim JS. Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level: a 6.4-year follow-up study of 482,472 Korean men. *Am J Epidemiol.* 2000;151:739–747.

21. Yi SW, Yi JJ, Ohrr H. Total cholesterol and all-cause mortality by sex and age: a prospective cohort study among 12.8 million adults. *Sci Rep.* 2019;9:1596.

22. Tanamas SK, Saulnier PJ, Hanson RL, Nelson RG, Hsueh WC, Sievers ML, et al. Serum lipids and mortality in an American Indian population: A longitudinal study. *J Diabetes Complications.* 2018;32:18–

23. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. 1995;274:539–544.

24. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. *Circulation* 1992;86:1046–

25. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. 2004;364:685–696.

26. Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. 2018;61:2277–2289.
27. Colantonio LD, Bittner V, Reynolds K, Levitan EB, Rosenson RS, Banach M, et al. Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. 2016;133:256–264.

28. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, et al. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens.* 2011;29:1802–

29. Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, et al. Haemoglobin A₁c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. *Diabetes Obes Metab.* 2018;20:1885–1893.

30. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, et al. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) Study. *Nephrol Dial Transplant.* 2011;26:3950–3954.

31. Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *Diabetes Care.* 2012;35:2317–

32. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. *Diabetes Care.* 2012;35:143–

33. Miselli MA, Nora ED, Passaro A, Tomasi F, Zuliani G. Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. *Cardiovasc Diabetol.* 2014;13:135.

34. Vega GL, Barlow CE, Grundy SM, Leonard D, DeFina LF. Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. *J Investig Med.* 2014;62:345–349.

35. Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, et al. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. *Heart Vessels.* 2014;29:35–41.

36. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. *N Engl J Med.* 2007;357:1301–1310.

37. Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J, et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes Care.* 2016;39:1424–1430.

38. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. 2012;307:2499–506.

39. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. 1996;124:261–271.
40. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. *Am J Med.* 1993;94:350–356.

**Supplementary Information**

Additional file 1: The RIACE Study Group. Additional file 2: Table S1: Baseline clinical features of study participants by quartiles of triglycerides. Table S2: Baseline clinical features of study participants by quartiles of HDL cholesterol. Table S3: Baseline clinical features of study participants by quartiles of TG:HDL. Additional file 3: Figure S1: Survival analysis by quartiles of triglycerides in males. Figure S2: Survival analysis by quartiles of triglycerides in females. Figure S3: Survival analysis by quartiles of HDL cholesterol in males. Figure S4: Survival analysis by quartiles of HDL cholesterol in females. Figure S5: Survival analysis by quartiles of TG:HDL in males. Figure S6: Survival analysis by quartiles of TG:HDL in females.

**Figures**
Figure 1

Survival analysis by quartiles of triglycerides in the whole cohort. Cumulative survival by Kaplan Meier-analysis (a) and Cox proportional hazards regression, adjusted for age and gender (b), plus CVD risk factors (c) plus complications/comorbidities (d), according to quartiles of triglycerides. Numbers (percentages) of deaths and HRs (95% CI) for mortality are shown for each group. HR = hazard ratio; CI = confidence interval.
Survival analysis by quartiles of HDL cholesterol in the whole cohort. Cumulative survival by Kaplan Meier-analysis (a) and Cox proportional hazards regression, adjusted for age and gender (b), plus CVD risk factors (c) plus complications/comorbidities (d), according to quartiles of HDL cholesterol. Numbers (percentages) of deaths and HRs (95% CI) for mortality are shown for each group. HR = hazard ratio; CI = confidence interval.
Survival analysis by quartiles of HDL cholesterol in the whole cohort. Cumulative survival by Kaplan Meier-analysis (a) and Cox proportional hazards regression, adjusted for age and gender (b), plus CVD risk factors (c) plus complications/comorbidities (d), according to quartiles of HDL cholesterol. Numbers (percentages) of deaths and HRs (95% CI) for mortality are shown for each group. HR = hazard ratio; CI = confidence interval.
Figure 3

Survival analysis by quartiles of TG:HDL in the whole cohort. Cumulative survival by Kaplan Meier-analysis (a) and Cox proportional hazards regression, adjusted for age and gender (b), plus CVD risk factors (c) plus complications/comorbidities (d), according to quartiles of TG:HDL ratio. Numbers (percentages) of deaths and HRs (95% CI) for mortality are shown for each group. TG:HDL = triglyceride:HDL cholesterol ratio; HR = hazard ratio; CI = confidence interval.
Figure 3

Survival analysis by quartiles of TG:HDL in the whole cohort. Cumulative survival by Kaplan Meier-analysis (a) and Cox proportional hazards regression, adjusted for age and gender (b), plus CVD risk factors (c) plus complications/comorbidities (d), according to quartiles of TG:HDL ratio. Numbers (percentages) of deaths and HRs (95% CI) for mortality are shown for each group. TG:HDL = triglyceride:HDL cholesterol ratio; HR = hazard ratio; CI = confidence interval.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.doc
- Additionalfile1.doc
- Additionalfile2.doc
- Additionalfile2.doc
• Additionalfile3.doc
• Additionalfile3.doc
• STROBEchecklistcohort.doc
• STROBEchecklistcohort.doc